pancreatic cancer and semaglutide What to know about new study showing weight loss drugs can lower risk Frontiers | Glucagon-like peptide-1 receptor

The Ozempic NAION lawsuit involves claims that Ozempic and other GLP-1 drugs may increase the risk of a serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION), which occurs when blood flow to the optic nerve is disturbed or cut off

In a retrospective analysis of 177 patients on oral semaglutide, weight loss velocity decelerates sharply after 3 months from 1.99 kg/month in the first month to 0.18 kg/month between months 6 and 12 and a 23% weight rebound is already measurable by month 18 (Makkar et al., 2026)

73 Another report mentioned trials in Crohns disease and even in multiple sclerosis , suggesting potential benefits

Based on a competitive inhibition mechanism, adding supraphysiological concentrations of glutamine (SPG) inhibited the uptake of neutral amino acids in oocytes expressing human SLC1A5 (ASCT2), the primary glutamine transporter in cancer cells [92,93]

Neither retatrutide nor tesamorelin holds MHRA marketing authorisation in the UK